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Abstract
Antifungal resistance in Candida and Aspergillus may be either intrinsic or acquired and may be encountered in the antifungal drug exposed
but also the antifungal drug-na€ıve patient. Prior antifungal treatment confers a selection pressure and notoriously raises the awareness of
possible resistance in patients failing therapy, thus calling for susceptibility testing. On the contrary, antifungal resistance in the drug-na€ıve
patient is less expected and therefore more challenging. This is particularly true when it concerns pathogens with acquired resistance which
cannot be predicted from the species identiﬁcation itself. This scenario is particularly relevant for A. fumigatus infections due to the
increasing prevalence of azole-resistant isolates in the environment. For Candida, infections resistance is most common in the context of
increasing prevalence of species with intrinsic resistance. Candida glabrata which has intrinsically reduced susceptibility to ﬂuconazole is
increasingly common particularly among the adult and elderly population on the Northern Hemisphere where it may be responsible for as
many as 30% of the blood stream infections in population-based surveillance programmes. Candida parapsilosis is prevalent in the paediatric
setting, at centres with increasing echinocandin use and at the southern or paciﬁc parts of the world. In the following, the prevalence and
drivers of intrinsic and acquired resistance in Aspergillus and Candida will be reviewed.
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Introduction
Resistance in Aspergillus and Candida has been increasingly
investigated and reported because standards for susceptibility
testing and associated breakpoints became available and as a
consequence of the increased use of antifungal compounds
[1–4].
Resistant infection can be encountered in the antifungal
drug-exposed patient due to selection of intrinsically resistant
species or isolates with acquired resistance belonging to
species that are normally susceptible. In both cases, resistance
may be expected as any antimicrobial therapy is associated
with a selection pressure and therefore risk of resistance.
Resistance can, however, also be encountered in the antifungal
drug-na€ıve patient and, again, can be due either to infection
with intrinsically resistant species or to isolates with acquired
resistance. Whereas resistance due to intrinsically resistant
species can be diagnosed through correct species identiﬁca-
tion, detection of isolates with acquired resistance is more
demanding and requires appropriate and carefully performed
susceptibility testing and endpoint interpretation [5].
New tools for rapid species identiﬁcation of Candida species
including the matrix-assisted laser desorption ionization
time-of-ﬂight mass spectrometry (MALDI-TOF MS), ﬂuores-
cence in situ hybridization (FISH), etc. have improved correct
species identiﬁcation at clinical microbiological routine
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laboratories. However, various challenges are still associated
with performance and interpretation of susceptibility testing
even though commercial tests are now available for most
antifungal compounds and clinical breakpoints have been
established [1,2,6–11]. Firstly, performance requires expertise
to obtain reproducible results, second the standardization of
commercial methods against the reference test is not perfect
for all drug–bug combinations leading to misclassiﬁcation of
susceptibility test results when reference breakpoints are
adopted, and ﬁnally for Aspergillus, such tests are not routinely
performed. Hence, the greatest diagnostic challenges related
to resistant infections lay with the correct and timely detection
of infections due to isolates with acquired resistance and
particularly so in the drug-na€ıve patients where, historically,
resistance has not been expected.
Resistance in Aspergillus
From an epidemiological point of view, less is known about the
true prevalence of resistant Aspergillus infections than about
resistant infections for most other organisms. This is due to
the fact that most routine laboratories do not susceptibility
test their Aspergillus isolates and many laboratories ﬁnd species
(or even genus) identiﬁcation of aspergilli difﬁcult. Additionally,
national surveillance programmes are lacking.
Intrinsic resistance
Aspergillus fumigatus is by far the most common species causing
human infection. The wild-type isolates are susceptible to all
the licensed mould active azoles (Table 1) and echinocandins
[3,4,12]. However, the A. fumigatus species complex includes
more than 30 sibling species which cannot be differentiated
morphologically from one another or from A. fumigatus.
Several of these have been isolates from humans and been
shown to be intrinsically resistant to one or more antifungals
(Table 2) [12–15]. Notably, however, a simple temperature
tolerance test (growth at temperatures higher than 48°C) can
discriminate between A. fumigatus and the sibling species.
Intrinsic amphotericin B resistance has been recognized in
A. terreus for many decades, but also A. ﬂavus and other less
common species have reduced susceptibility to amphotericin B
[3]. Importantly, a number of these rare Aspergillus species are
also resistant to azoles and in some cases also to echinocan-
dins posing obvious challenges for patient management
(Tables 1 and 2). Hence, careful species identiﬁcation is
mandatory for clinically important isolates.
Acquired resistance in AF-na€ıve patients
Azole-resistant A. fumigatus infections have been reported in a
number of countries. Most reports derive from Europe and
involve a single molecular resistance mechanism consisting of a
34-bp tandem repeat TR34 in the promotor region of the azole
target CYP51A gene and a point mutation in the target gene
itself leading to an L98H amino acid substitution (TR34/L98H).
This resistance mechanisms has been detected in isolates
deriving from Austria, Belgium, Denmark, Germany, France,
the Netherlands, Norway, Spain, Sweden and the UK [16–23]
and outside Europe in China, India and Iran [24,25] (Verweij,
personal communication). Notably, 61% of the global market
share of agricultural fungicides is used in these Western
TABLE 1. Intrinsic susceptibility pattern and epidemiological cut-off values (ECOFFs) for Aspergillus species and mould active
azoles. Data compiled from [3,4,12]
Aspergillus (S/I/R (ECOFF))a
calidoustus ﬂavus fumigatus nidulans niger terreus versicolor
Amphotericin B IE (NDb) IE (4 mg/L) S (1 mg/L) NDc S (1 mg/L) R (4 mg/L) NDb
Itraconazole R (NDb) S (1 mg/L) S (1 mg/L) S (1 mg/L) IE (4 mg/L) S (0.5 mg/L) NDb
Posaconazole R (NDb) IE (0.5 mg/L) S (0.25 mg/L) IE (0.5 mg/L) IE (0.5 mg/L) S (0.25 mg/L) NDb
Voriconazole R (NDb) IE (2 mg/L) S (1 mg/L) S (1 mg/L) IE (2 mg/L) IE (2 mg/L) NDc
ECOFF: epidemiological cut-off values; IE: insufﬁcient evidence to suggest whether this species is a good target for the compound in question. MICs are higher than for Aspergillus
fumigatus, but there is insufﬁcient clinical data to suggest whether this translates into poorer efﬁcacy; ND: not done due to insufﬁcient amount of data for ECOFF setting (low
number of MIC values or data set).
aS/I/R: intrinsically susceptible/intermediate/resistant.
bMIC range higher than that for A. fumigatus.
cMIC range similar to that for A. fumigatus.
TABLE 2. Intrinsic resistance (R) and variable (V) suscepti-
bility in Aspergillus
AMB Azoles Echinocandins
Aspergillus section fumigati
A. fumigatiafﬁnis R R
A. lentulus R R V
N. pseudoﬁscheri V R
A. viridinutans R R
N. udagawae R R (vor)
A. terreus (and A. alabamensis) R
A. ﬂavus R R
A. versicolor (and A. sydowi) R V
A. calidoustus R V
A. allilaceus V V
Data compiled from [12–15].
Vor, Voriconazole.
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European and Asia Paciﬁc regions, and thus, the prevalence of
TR34/L98H correlates with the geographical use of these
agents [23]. Two additional resistant genotypes have been
demonstrated among isolates from the European environment
or from azole-na€ıve patients, namely isolates harbouring the
TR46/Y121F/T289A or the G432S alterations [26,27]. Altera-
tions involving tandem repeats in the promotor region of
CYP51A and amino acid changes at codons Y121, T289 and
G432 have similarly been found in azole pesticide-resistant
isolates of the common plant pathogen Mycosphaerella gramini-
cola, suggesting these codons are hot spots for possible
selection via the agricultural azoles [23]. The true prevalence
of the environmental type resistant isolates is largely unknown.
In the Netherlands, they accounted for approx. 10% in 2007, in
Danish soil samples for 8% and in Danish patients approx. 4%
in 2009–11 [19,28,29].
Acquired resistance in AF-exposed patients
A number of reports have documented the selection of azole
resistance during treatment. Most reports concern long-term
treatment in patients with allergic or chronic forms of
aspergillosis [29–37]. The majority of isolates harbour muta-
tions in the target gene CYP51A, but other mechanisms are
important as well, including efﬂux pumps [38] and target gene
upregulation encoded by a mutation in the hapE gene [31,39].
Acquired azole resistance has also been reported in A. terreus
and A. ﬂavus, which poses obvious challenges regarding clinical
management of related infections as these two species have
intrinsically reduced susceptibility to amphotericin B [40,41].
Acquired resistance to amphotericin B in Aspergillus has not
been described so far, and only a single case of mechanistically
characterized acquired echinocandin resistance has been
reported [42]. Susceptibility testing of Aspergillus and echino-
candins is, however, even more challenging than susceptibility
testing of azoles and amphotericin B due to the lack of total
inhibition in vitro and therefore no clear endpoint. Hence,
acquired resistance to echinocandins may be underdiagnosed
and indeed breakthrough cases have been described in patients
receiving echinocandin therapy [43,44].
Size of the problem
A global study involving 19 countries reported overall
prevalence of azole resistance of 3.2% and ranging from 0 to
25.5% among the participating centres [16]. Notably, no
centres testing at least 100 isolates failed to detect resistant
isolates. It is well known that culture is an insensitive diagnostic
test, and hence, the molecular approach with direct detection
in patient samples is attractive. A recent study using direct
molecular detection of A. fumigatus and of alterations on the
codons most commonly involved in azole resistance (G54, L98,
G138 and M220) found an astonishingly high rate of resistance
markers (55%) in samples from patient mainly suffering from
chronic forms of aspergillosis in the UK [17,45]. However,
using the same technique for Danish patients at risk for acute
or chronic forms of aspergillosis and undergoing bronchoscopy
with galactomannan antigen determination, 3.3 and 4.3%
resistance was detected by molecular and conventional
susceptibility tests, respectively [46]. It is not fully understood
why these two studies reported such different rates of
resistance, but a reasonable and conservative estimate of the
global prevalence of azole resistance in Aspergillus appears to
be 3–6%. This still raises concern as resistance was a very
uncommon event before the turn of the millennium and as
resistance is found also in drug-na€ıve patients.
Antifungal Resistance in Candida
The epidemiology of candidaemia is particularly well docu-
mented in the Nordic countries due to ongoing nationwide
surveillance programmes [47–50]. Such programmes provide
precise ﬁgures for the burden of disease in entire populations,
without centre bias, but are less sensitive with respect to the
signiﬁcance of acquired resistance. This is a consequence of the
study designs, as epidemiological studies include only the initial
isolate typically at the time of the lowest antifungal exposure.
This is a sound strategy from an epidemiological point of view
as otherwise the data set would be skewed due to repeated
isolates. With this in mind, the following section summarizes
the contemporary and available data on resistance in Candida.
Intrinsic resistance
The intrinsic susceptibility pattern of the various Candida
species is summarized in Table 3. Candida glabrata and
C. parapsilosis represent the two most prevalent species with
reduced azole and echinocandin susceptibility, respectively,
and their prevalence is shown in a global perspective in
Fig. 1. Candida glabrata is particularly prevalent on the
Northern Hemisphere with incidence rates as high as 30%
in some centres. It is signiﬁcantly more common in the
elderly population, whereas the opposite is true for C. par-
apsilosis [47]. Other drivers of selection of resistant species
include prior antifungal drug exposure where choice of
compound as well as dosing (suboptimal) and duration (more
than a week) are important [51–53]. Finally, a recent report
has suggested that various antibacterial compounds may also
drive the selection of resistance. The underlying mechanism
may be altered gut ﬂora or the low-grade antifungal effect
exerted by some antibacterial compounds, such as metroni-
dazole [54]. Increasing use of echinocandins has been linked
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to an increasing proportion of blood stream infections due to
C. parapsilosis [55,56]. It is important to be aware of the fact,
however, that a considerable usage of oral antifungals takes
place outside the hospital [57]. For example, more than
two-thirds of the systemic azole use is prescribed in the
primary healthcare sector in Denmark and presumably for
rather benign conditions like toenail infection (itraconazole),
vaginitis (ﬂuconazole and itraconazole) and various skin
conditions (e.g. pityriasis) [57]. As invasive infection derive
from the colonizing Candida ﬂora, this may deserve more
attention with respect to antibiotic stewardship policies [57].
Acquired resistance
Acquired resistance is less common than intrinsic resistance.
One of the reasons is that fungi do not exchange resistance
genes via plasmids, and hence, selection of resistance takes
place in the individual patient during individual antifungal use.
Various reports suggest intrinsic resistance may be emerging.
Pfaller et al. reported that high-level ﬂuconazole resistance
(MIC ≥16 mg/L), and thus clearly above the susceptibility
breakpoint of 2 mg/L, was rare in C. albicans and C. dubliniensis
isolates (2.0% and 3.9%, respectively) but found in as many as
6.8% and 9.0% of the C. parapsilosis and C. tropicalis isolates,
respectively, among a quarter of a million isolates from 41
countries [58]. Oxman et al. reported that 19% of their Candida
infections involved ﬂuconazole-resistant isolates (again with
MICs ≥16 mg/L) at two tertiary cancer centres in the US and
notably that in a third of these cases, resistance was acquired
rather than intrinsic [59]. Such a ﬁnding questions the use of
species identiﬁcation alone as a driver of antifungal treatment.
Finally, 13% of ﬂuconazole-resistant C. glabrata (MIC ≥64 mg/
L) were cross-resistant to echinocandins among isolates
collected in 2006–10, whereas no such isolates were found in
the period 2001–4 at the same institution [60].
As stated earlier, acquired resistance is rarely reported in
epidemiological surveillance programmes of candidaemia.
Interestingly, notable discrepancies were found between the
resistance rates among deep-seated isolates and mucosal
isolates in a recent study of voriconazole susceptibility [61].
Similarly, we noted ﬂuconazole MICs above the EUCAST
susceptibility in 15% and 20% of mucosal C. albicans and
C. dubliniensis isolates in Denmark (M.C. Arendrup, Personal
observation). Taken together, mounting evidence suggests
acquired resistance may be an emerging and underdiagnosed
entity.
Possible link to agricultural azole use?
Whereas the link between agricultural use of azole pesticides
and the emergence of azole-resistant Aspergillus has been
suggested beyond reasonable doubt, it is less clear whether
agricultural pesticides may also be drivers of azole resistance
in Candida. Three observations, however, suggest this may be
a relevant concern. The ﬁrst one concerns susceptibility in
Candida isolated from the surface of fruit harvested from
non-organic vs. organic farms. Not surprisingly, ﬂuconazole
MICs were higher for Candida isolated from non-organic fruit
(16–64 mg/L vs. 1–8 mg/L) [62]. Furthermore, in the same
study, the fungal pesticide myclobutanil was shown to induce
efﬂux pump expression in C. glabrata in vitro [62]. The second
observation concerns C. tropicalis isolates with reduced sus-
ceptibility to ﬂuconazole found in unrelated patients at
various Japanese hospitals [63]. These isolates were found
to share indistinguishable pulse ﬁeld gel electrophoresis
patterns and to belong to the same diploid sequence
genotypes as C. tropicalis with reduced ﬂuconazole suscepti-
bility found in soil samples and to possess reduced suscep-
tibility to agricultural pesticides [63]. Finally, a wild Brazilian
TABLE 3. Intrinsic susceptibility pattern for Candida species.
EUCAST breakpoints have been established for the common
Candida species allowing classiﬁcation if wild-type isolates
into S, I and R categories. For the uncommon Candida
species, breakpoints have not been established. For these
species, an ‘X’ denotes that the MICs for the antifungal
compound are elevated compared with those for Candida
albicans
AMB ECS FCO Comments
Common Candida species
C. albicans S S S
C. dubliniensis S S S Closely related
to C. albicans;
ﬂuconazole
resistance
acquired more
easily
C. glabrata S S I Efﬂux pumps
often induced
during azole
therapy
C. krusei S S R
C. parapsilosis S I S
C. tropicalis S S S
Uncommon Candida species
C. lusitaniae X
C. fermentati X
C. guilliermondii X X
C. metapsilosis X Closely related
to C. parapsilosis
C. orthopsilosis X Closely related
to C. parapsilosis
C. cifferrii X
C. inconspicua X
C. humicula X
C. lambica X
C. lipolytica X
C. norvegensis X
C. palmioleophila X
C. rugosa X
C. valida X
S. cerevisiaea X Closely related
to C. glabrata
ECS: echinocandins; FCO: ﬂuconazole.
aAnamorphic state is C. robusta.
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porcupine with documented invasive candidiasis due to a
C. albicans isolate with efﬂux pump-mediated high-level azole
resistance was recently found [64]. Although the evidence is
limited and circumstantial, it cannot be excluded that the use
of agricultural azoles may drive antifungal resistance in
Aspergillus, but also in Candida.
Conclusion and Future Perspectives
In conclusion, resistant Candida and Aspergillus infection are
increasingly encountered in the antifungal drug-na€ıve patient
due to increasing incidence rates of C. glabrata (particularly at
the northern hemisphere), C. parapsilosis (particularly at centres
with a high echinocandin use) and due to increasing proportion
of environmental A. fumigatus isolates harbouring azole resis-
tancemechanisms. In vivo selection of acquired resistance during
medical treatment is increasingly reported for Candida in
patients typically receiving more than 3 weeks of echinocandin
therapy and in patients with chronic forms of aspergillosis on
long-term azole treatment. In numbers, 20–30% of candidaemia
cases today involve species with intrinsic resistance to either
ﬂuconazole or echinocandins. This is a signiﬁcant change, as
C. albicans (which is intrinsically susceptible to all drug classes)
typically accounted for at least 85% of the cases in the
preﬂuconazole, pre-echinocandin era. Azole resistance in
Aspergillus overall is probably around 4% but increasing. The
drivers of this changing epidemiology are antifungal use in the
hospitals but importantly also in the primary healthcare sector,
and particularly for Aspergillus the high use for plant protection.
In any case, we only see the tip of the iceberg due to
challenges associated with antifungal susceptibility testing, the
design of epidemiological surveillance programmes and the
infrequent performance of susceptibility testing of aspergilli.
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